In contrast, CISD1 showed a significant negative correlation with MSI in LUAD, CESC, and PRAD (Fig. 8B), suggesting that patients with high CISD1 expression are less likely to respond to immunotherapies in these cancers. This evidence concerns the gene CISD1 and prostate adenocarcinoma.